Evidence-graded ingredient cards.
FprovisionalJuly 2026 (watch for first-in-human PK/efficacy trials — that would be the first thing to move any grade off F)
metabolic · fat loss (adipose-direct) · NAD⁺ / cellular energy
links to → slu-pp-332, mots-c, humanin +2
◂ 5 inboundFprovisionalJuly 2026 (status: development permanently discontinued 2019 on nephrotoxicity; the mechanism lives on in oncology "hunter-killer" peptides, but Adipotide itself is not returning absent a fundamentally safer redesign)
fat loss (vascular-ablation) · anti-obesity · (originally oncology / anti-angiogenic)
links to → aod-9604, 5-amino-1mq, slu-pp-332 +1
◂ 3 inboundAprovisionalJuly 2026 (approval status stable; note ongoing post-marketing safety surveillance and any label/indication changes)
(approved:) photoprotection / EPP phototoxicity-prevention · MC1R-driven eumelanin synthesis · (gray-market, as "Melanotan-1":) cosmetic tanning
links to → melanotan-ii, pt-141
◂ 3 inboundCprovisionalJuly 2026
hair appearance (cosmetic) · scalp · (reference:) dermal papilla / anagen-phase biology
links to → ghk-cu, palmitoyl-tripeptide-1-5
◂ 2 inboundFprovisionalJuly 2026 (status: foundational animal data, no human endurance trials, WADA-banned; watch AMPK-activator drug development — e.g. next-gen activators like O304 — rather than AICAR itself)
metabolic · endurance / performance (exercise mimetic) · fat oxidation
links to → slu-pp-332, mots-c, 5-amino-1mq
◂ 4 inboundBprovisionalJuly 2026 (fast-moving — re-check Phase 3 progress)
metabolic · obesity / weight · type-2 diabetes (investigational)
links to → cagrilintide, semaglutide, retatrutide
◂ 5 inboundFprovisionalJuly 2026 (status stable — a failed/abandoned obesity program; unlikely to change absent a new indication with real data)
(intended:) fat loss / lipolysis · (failed:) obesity/weight-loss drug · (gray-market:) joint/recovery
links to → semaglutide, tirzepatide, 5-amino-1mq +4
◂ 5 inboundCprovisionalJuly 2026
skin appearance (cosmetic) · expression lines / dynamic wrinkles
links to → snap-8, matrixyl, ghk-cu +1
◂ 15 inboundBprovisional2026-07-07
skin appearance (cosmetic) · fine lines and photoaging appearance · hyperpigmentation appearance
links to → retinol, ghk-cu, niacinamide +1
◂ 8 inboundBprovisionalJuly 2026 (fast-moving — re-check the 2026 tirzepatide-combination readouts)
muscle preservation / anti-ActRII · body composition · metabolic (investigational)
links to → follistatin, semaglutide, tirzepatide
◂ 2 inboundBprovisionalJuly 2026 (regulatory status is evolving — re-check the PCAC outcome and any Federal Register rule)
tissue repair · gastrointestinal · tendon & ligament
links to → tb-500, kpv, mots-c
◂ 7 inboundBprovisionalJuly 2026 (fast-moving — re-check the late-2026 FDA decision on CagriSema)
metabolic · obesity / weight · amylin (investigational)
links to → semaglutide, retatrutide
◂ 8 inboundAprovisional2026-07-08
skin appearance (cosmetic) · barrier support · hydration
links to → niacinamide, hyaluronic-acid, ectoin +1
◂ 41 inboundCprovisionalJuly 2026 (watch for the updated 2025 Cochrane vascular-dementia review and any independent, non-industry RCT — that would be decisive)
neuroprotection · stroke recovery · TBI
links to → semax, selank, dihexa
◂ 2 inboundCprovisionalJuly 2026
graded evidence reference
links to → cjc-1295, ipamorelin, sermorelin +1
◂ 5 inboundBprovisionalJuly 2026
GH secretagogue / GHRH analog · body composition (research context)
links to → sermorelin, ipamorelin, cjc-1295-ipamorelin +1
◂ 9 inboundBprovisionalJuly 2026 (the field's need: adequately-powered Phase 2/3 trials with validated senescence biomarkers — many ongoing (sepsis, PAD, osteoarthritis); the open question is whether human clearance finally translates to clinical benefit)
senescent-cell clearance (senolytic) · anti-inflammatory / anti-SASP · longevity / healthspan (investigational)
links to → foxo4-dri, nad-plus, epitalon +1
◂ 0 inbound · orphanFprovisionalJuly 2026 (status: preclinical + retracted foundation + failed related clinical program; unlikely to improve without new, independent human data)
nootropic / procognitive · synaptogenesis (synapse-building) · (preclinical only; heavily gray-market)
links to → cerebrolysin, semax, selank
◂ 3 inboundCprovisionalJuly 2026 (US review status evolving — re-check the July PCAC/Emideltide outcome)
sleep / circadian · (also studied:) withdrawal, stress, pain — research context
links to → epitalon, semax
◂ 2 inboundBprovisional2026-07-07
skin appearance (cosmetic) · barrier support · hydration
links to → matrixyl, ghk-cu
◂ 4 inboundBprovisionalJuly 2026 (Phase 3 obesity enrolling; eloralintide + tirzepatide combination and Phase 3 readouts are the catalysts — and the real test of whether ~20% holds at scale)
weight management / obesity · selective amylin-receptor agonism (satiety) · cardiometabolic improvement
links to → pramlintide, cagrilintide, petrelintide +3
◂ 2 inboundCprovisionalJuly 2026 (US review status evolving — re-check the July PCAC outcome and any Federal Register rule)
longevity / telomere · circadian / sleep · antioxidant (research context)
links to → dsip, semax
◂ 6 inboundCprovisional2026-07-09
skin appearance (cosmetic) · antioxidant (appearance) · soothing (appearance)
links to → pdrn, ghk-cu, what-are-exosomes-skincare
◂ 4 inboundFprovisionalJuly 2026
muscle / myostatin inhibition · (studied:) muscular-dystrophy gene therapy — research context
links to → igf-1-lr3
◂ 3 inboundFprovisionalJuly 2026 (Alzheimer's program failed/effectively discontinued; the HGF/MET pathway continues only via oral ATH-1105 in ALS — the remaining test of whether the mechanism helps any neurodegenerative disease)
neurodegeneration (Alzheimer's — failed) · HGF/MET modulation · neuroprotection (hypothesized)
links to → dihexa, aod-9604, adipotide +1
◂ 0 inbound · orphanDprovisionalJuly 2026 (status: preclinical; the decisive event would be a first-in-human Phase 1 — repeatedly anticipated, not yet done)
senolytic (senescent-cell clearance) · longevity / healthspan · tissue-function restoration
links to → nad-plus, epitalon, dihexa
◂ 2 inboundBprovisional2026-07-07 (US injectable status: interim — Category 2 removed 15 April 2026, PCAC review scheduled before end-February 2027; recheck after outcome)
skin appearance (cosmetic) · antioxidant · (research context:) tissue repair
links to → ahk-cu, matrixyl, snap-8 +6
◂ 43 inboundBprovisionalJuly 2026
GH secretagogue / ghrelin agonist · (approved: GH-deficiency diagnostic) · body composition (off-label)
links to → ghrp-6, ipamorelin, cjc-1295 +1
◂ 4 inboundBprovisionalJuly 2026
GH secretagogue / ghrelin agonist · appetite stimulation · (research context)
links to → ghrp-2, ipamorelin
◂ 4 inboundAprovisionalJuly 2026 (watch: better-bioavailability oral forms (liposomal/acetyl) with real RCTs; IV skin-lightening remains unapproved and risk-flagged)
antioxidant / detox (endogenous) · skin lightening / brightening · anti-pigmentation (melasma)
links to → melanotan-ii, afamelanotide, nad-plus
◂ 1 inboundBprovisionalJuly 2026
GH secretagogue / ghrelin agonist · cardiac (CD36) · (studied:) GH deficiency, heart failure — research context
links to → ghrp-6, ghrp-2, ipamorelin
◂ 1 inboundCprovisionalJuly 2026 (watch for any first-in-human interventional trial — that would change the grades materially)
mitochondrial · longevity-biomarker · (preclinical:) neuroprotection (Alzheimer's / amyloid)
links to → mots-c, ss-31, igf-1-lr3
◂ 2 inboundAprovisional2026-07-07
skin appearance (cosmetic) · hydration · humectant
links to → ghk-cu, matrixyl
◂ 32 inboundFprovisionalJuly 2026
muscle / anabolic (research) · cell-culture growth factor (its actual established use)
links to → follistatin, cjc-1295
◂ 3 inboundBprovisionalJuly 2026
GH secretagogue / ghrelin-receptor agonist · body composition (research context)
links to → cjc-1295, cjc-1295-ipamorelin, ghrp-2 +1
◂ 10 inboundBprovisionalJuly 2026 (active clinical pipeline — watch for Phase 2/3 progress in IVF triggering and HSDD; approval would move several grades)
reproductive-axis stimulation (GnRH→LH/FSH) · fertility / IVF triggering · sexual desire / arousal (HSDD)
links to → pt-141, adipotide
◂ 1 inboundCprovisionalJuly 2026 (FDA compounding status evolving — re-check the July PCAC outcome)
anti-inflammatory · gut / IBD · (also studied:) dermatitis, wound healing, antimicrobial — research context
links to → melanotan-ii, pt-141, bpc-157
◂ 3 inboundDprovisionalJuly 2026 (status: celiac Phase 3 failed 2022, no approved indication; watch only for revived development in adjacent barrier-disease indications)
intestinal barrier / tight-junction regulation · celiac disease (adjunct, investigational) · "leaky gut" (the concept it actually targets)
links to → bpc-157, kpv, aod-9604 +1
◂ 1 inboundAprovisionalJuly 2026
metabolic · type-2 diabetes · obesity / weight
links to → semaglutide, tirzepatide, retatrutide +1
◂ 2 inboundAprovisionalJuly 2026 (watch: engineered LL-37 analogs/fragments that dissociate antimicrobial from pro-inflammatory activity — the field's key therapeutic goal)
(defensive:) antimicrobial · wound healing · angiogenesis
links to → kpv, bpc-157, tb-500 +1
◂ 0 inbound · orphanBprovisionalJuly 2026
skin appearance (cosmetic) · fine lines & wrinkles · (reference:) collagen/ECM signalling
links to → argireline, ghk-cu, palmitoyl-tripeptide-1-5 +3
◂ 20 inboundAprovisionalJuly 2026 (China-approved; watch for global (non-Chinese) trials and any ex-China regulatory filing, which would change the region-qualified grades)
metabolic · weight loss · glycaemic (T2D)
links to → survodutide, tirzepatide, retatrutide +1
◂ 2 inboundCprovisionalJuly 2026
skin tanning · sexual arousal (gray-market / research)
links to → pt-141
◂ 6 inboundDprovisionalJuly 2026 (watch for any controlled human data — the field is preclinical-heavy; that would move the grades)
muscle growth / repair · satellite-cell (stem-cell) activation · tissue repair
links to → igf-1-lr3, follistatin, bimagrumab +3
◂ 0 inbound · orphanBprovisionalJuly 2026
GH secretagogue (oral) · body composition · slow-wave sleep
links to → ghrp-6, ghrp-2, ipamorelin +4
◂ 3 inboundCprovisionalJuly 2026 (US review status evolving — re-check the July PCAC outcome and any Federal Register rule)
metabolic · mitochondrial · insulin sensitivity
links to → bpc-157
◂ 8 inboundAprovisionalJuly 2026 (watch: longer/larger RCTs and the disease-specific trials — neurodegeneration, metabolic — that could finally close or confirm the biomarker-vs-outcome gap)
longevity / healthy-aging (claimed) · cellular energy / mitochondrial · DNA repair / sirtuins
links to → mots-c, 5-amino-1mq, slu-pp-332 +2
◂ 5 inboundBprovisional2026-07-07
skin appearance (cosmetic) · antioxidant · anti-inflammaging (mechanism-level)
links to → ectoin, ghk-cu, what-is-inflammaging-naringenin
◂ 1 inboundAprovisional2026-07-07
skin appearance (cosmetic) · barrier support · hyperpigmentation appearance
links to → ghk-cu, matrixyl, argireline
◂ 94 inboundCprovisionalJuly 2026
nootropic / cognitive · neuroprotection · BDNF/NGF (approved in Russia: cognitive disorders)
links to → semax, selank
◂ 0 inbound · orphanBprovisionalJuly 2026 (fast-moving — re-check the FDA obesity decision and T2D filing)
metabolic · obesity / weight · type-2 diabetes (investigational)
links to → amycretin, semaglutide, retatrutide
◂ 1 inboundAprovisionalJuly 2026 (watch: OXTR-genotype-stratified / precision-medicine trials and any dose/subgroup autism signal — the field's remaining hope after SOARS-B)
(approved:) labor induction / uterotonic · lactation · (investigational/hyped:) social bonding / trust / empathy
links to → vip, kisspeptin-10, pt-141 +2
◂ 0 inbound · orphanCprovisionalJuly 2026
skin appearance (cosmetic) · fine lines & firmness · (reference:) collagen/ECM signalling
links to → matrixyl, ghk-cu, argireline +2
◂ 2 inboundCprovisional2026-07-09
skin appearance (cosmetic) · soothing (appearance) · hydration (appearance)
links to → exosomes, ghk-cu, what-is-pdrn-skincare
◂ 5 inboundCprovisionalJuly 2026 (PERFORMA Phase 3 MASH H2 2026, end-of-Phase-2 FDA meeting, and AUD/ALD readouts are the catalysts — and the test of whether liver/muscle differentiation beats raw-magnitude competition)
MASH / fatty-liver (lead) · weight management / obesity · muscle-sparing weight loss
links to → survodutide, mazdutide, retatrutide +2
◂ 0 inbound · orphanBprovisionalJuly 2026 (fast-moving: Phase 3 start H2 2026, ZUPREME-2 diabetes readout, and the CT-388 combination Phase 2 are the catalysts to watch)
weight management / obesity · amylin-receptor agonism (satiety / leptin resensitization) · combination-ready (non-incretin partner)
links to → pramlintide, cagrilintide, amycretin +4
◂ 1 inboundAprovisionalJuly 2026 (pramlintide's status is stable/old; the moving part is the successor class — re-check Cagrilintide/Petrelintide/Eloralintide milestones)
glycaemic (T1D & T2D adjunct) · postprandial glucose/glucagon control · modest weight loss
links to → cagrilintide, amycretin, semaglutide
◂ 3 inboundBprovisionalJuly 2026
sexual desire / arousal (approved: female HSDD) · erectile function (off-label)
links to → melanotan-ii
◂ 6 inboundAprovisionalJuly 2026 (the field's key open question: a human RCT with a genuine longevity/healthspan endpoint — none has succeeded yet; intermittent-dosing and rapalog selectivity are the active frontiers)
longevity / geroprotection (off-label) · mTOR inhibition / autophagy · immunosuppression (approved)
links to → nad-plus, epitalon, foxo4-dri +4
◂ 1 inboundBprovisionalJuly 2026 (fast-moving — re-check TRIUMPH-2/-3 readouts and any regulatory filing)
metabolic · obesity / weight · type-2 diabetes (investigational)
links to → semaglutide, tirzepatide, cagrilintide
◂ 11 inboundAprovisional2026-07-07
skin appearance (cosmetic) · fine lines and photoaging appearance · texture (appearance of smoother skin)
links to → ghk-cu, niacinamide, matrixyl +2
◂ 71 inboundCprovisionalJuly 2026
anxiolytic (approved: GAD) · neuro / cognitive (secondary) · immunomodulatory (research context)
links to → semax
◂ 3 inboundAprovisionalJuly 2026
metabolic · type-2 diabetes · obesity / weight
links to → tirzepatide, liraglutide, retatrutide
◂ 16 inboundCprovisionalJuly 2026 (US review status evolving — re-check the July PCAC outcome and any Federal Register rule)
neuro / cognitive · neuroprotection · BDNF (research context)
links to → dsip
◂ 6 inboundBprovisionalJuly 2026
GH secretagogue / GHRH analog · (approved historically: pediatric GHD + diagnostics) · adult GH optimization (off-label)
links to → cjc-1295, ipamorelin, cjc-1295-ipamorelin +1
◂ 5 inboundFprovisionalJuly 2026 (the moving part is the successor SLU-PP-915 and any first-in-human work; re-check whether ERR-agonism reaches clinical trials)
metabolic · fat loss · endurance / performance
links to → 5-amino-1mq, mots-c, semaglutide
◂ 8 inboundFprovisionalJuly 2026 (status: preclinical; the decisive event would be a first-in-human trial — none yet; watch Myonid/Pelagos ERR-agonist pipelines)
metabolic · endurance / aerobic capacity (exercise mimetic) · mitochondrial biogenesis / fat oxidation
links to → slu-pp-332, aicar, mots-c +1
◂ 0 inbound · orphanCprovisionalJuly 2026
skin appearance (cosmetic) · expression lines / dynamic wrinkles
links to → argireline, matrixyl, ghk-cu +1
◂ 7 inboundBprovisional2026-07-09
skin appearance (cosmetic) · emollient · hydration
links to → ceramides, hyaluronic-acid, niacinamide
◂ 4 inboundAprovisionalJuly 2026 (status evolving — accelerated approval requires a confirmatory trial; re-check the confirmatory-trial outcome and any label expansion)
mitochondrial · (approved:) Barth-syndrome muscle strength · (research/failed:) heart failure
links to → mots-c, humanin
◂ 1 inboundBprovisionalJuly 2026 (fast-moving — additional SYNCHRONIZE and LIVERAGE read-outs expected through 2026; re-check obesity + MASH Phase 3 completeness and any regulatory filing)
metabolic · weight loss · MASH / hepatic fat (the differentiator)
links to → tirzepatide, retatrutide, semaglutide +2
◂ 2 inboundBprovisionalJuly 2026 (established cosmetic active; status stable)
cosmetic · anti-wrinkle (expression/dynamic lines) · muscle-relaxing (topical, biomimetic)
links to → argireline, snap-8, matrixyl +2
◂ 1 inboundCprovisionalJuly 2026 (US review status evolving — re-check the July PCAC outcome and any Federal Register rule)
tissue repair · wound healing · angiogenesis
links to → bpc-157, thymosin-alpha-1
◂ 5 inboundAprovisionalJuly 2026
GHRH analog / GH secretagogue · visceral fat (approved: HIV-lipodystrophy) · (off-label:) body composition / liver fat
links to → sermorelin, cjc-1295, ipamorelin +1
◂ 4 inboundBprovisionalJuly 2026 (status: Phase 2/3 investigational; the open questions are Phase 3 confirmation and cardiovascular safety — and whether any CNS-monoamine drug can compete with the incretin era)
weight management / obesity (appetite ↓ + energy expenditure ↑) · CNS monoamine modulation · (originally: neurodegeneration — modest)
links to → semaglutide, tirzepatide, orforglipron +5
◂ 1 inboundCprovisionalJuly 2026 (status: long Russian clinical use, unapproved in West; the decisive future signal would be independent, non-affiliated replication of the immune/geroprotective claims)
immune support / immunocorrection · thymic / T-cell restoration · geroprotection (anti-aging, claimed)
links to → epitalon, thymosin-alpha-1
◂ 1 inboundBprovisionalJuly 2026 (US compounding status evolving — re-check)
immune modulation · antiviral (hepatitis) · vaccine adjuvant
links to → tb-500, bpc-157
◂ 3 inboundAprovisionalJuly 2026
metabolic · type-2 diabetes · obesity / weight
links to → semaglutide, retatrutide, cagrilintide +1
◂ 11 inboundBprovisional2026-07-11
skin appearance (cosmetic) · hyperpigmentation appearance · even tone / brightening
links to → niacinamide, vitamin-c, what-is-tranexamic-acid
◂ 1 inboundAprovisionalJuly 2026 (watch: FDA compounding status, and whether any independent (non-Shoemaker) controlled trial of intranasal VIP in CIRS or inflammatory disease appears — that would be decisive)
anti-inflammatory / immunoregulation · circadian (SCN) · vasodilation / bronchodilation
links to → cerebrolysin, thymalin, afamelanotide +2
◂ 1 inboundAprovisional2026-07-07
skin appearance (cosmetic) · antioxidant · hyperpigmentation appearance
links to → ghk-cu, niacinamide, retinol +2
◂ 45 inboundFprovisionalJuly 2026 (the decisive event would be the first actual combination study — none exists yet; until then "synergy" stays hypothetical)
soft-tissue healing (tendon/ligament/muscle) · recovery · angiogenesis + cell-migration (combined rationale)
links to → bpc-157, tb-500, cjc-1295-ipamorelin +1
◂ 0 inbound · orphan